Medical treatment of autism spectrum disorder in children: Current evidence, controversies, and clinical challenges

Table 5 Clinical algorithm for selecting methylphenidate vs atomoxetine in children with autism spectrum disorder and attention-deficit/hyperactivity disorder symptoms

First-line medication choice
MPH is recommended as initial pharmacotherapy in most children with ASD and comorbid ADHD symptoms, provided that no major tolerability concerns are present. MPH demonstrates the largest pooled effect size for hyperactivity reduction (SMD: -0.78) and has rapid onset of action (within days)
ATX is recommended as first-line therapy when:
The child has a history of stimulant-induced irritability, behavioral activation, or emotional dysregulation
Comorbid anxiety, tics, or sleep disturbance is present
Parents prefer a non-stimulant medication
Cardiac risk factors delay or preclude stimulant use
Stepwise treatment approach
Initiate MPH at low dose and titrate gradually based on response and tolerability
Reassess after 2-4 weeks. If inadequate response or intolerable adverse effects occur, switch to ATX
If ATX is started first and response remains suboptimal after 6-8 weeks of optimized dosing, switch to MPH
Combination therapy (MPH + ATX) may be considered only in specialist care after monotherapy failure, with clear target symptoms and close monitoring
Clinical considerations
MPH is associated with a higher risk of appetite suppression and irritability but provides faster and stronger symptom reduction
ATX offers more stable behavioral control, is better tolerated in emotionally reactive children, and may improve global ASD severity when combined with risperidone
Both agents require monitoring of appetite, sleep, heart rate, blood pressure, and behavioral changes at baseline and follow-up visits

MPH: Methylphenidate; ASD: Autism spectrum disorder; ADHD: Attention-deficit/hyperactivity disorder; SMD: Standardized mean difference; ATX: Atomoxetine.